1. Academic Validation
  2. Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives

Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives

  • Bioorg Med Chem Lett. 2014 Aug 15;24(16):3961-3. doi: 10.1016/j.bmcl.2014.06.034.
Junichiro Yamamoto 1 Nobuyoshi Amishiro 2 Kazuhiko Kato 2 Yoshihisa Ohta 2 Yoji Ino 2 Mitsuharu Araki 2 Tetsuya Tsujita 2 Seiho Okamoto 2 Takeshi Takahashi 2 Hideaki Kusaka 2 Shiro Akinaga 2 Yoshinori Yamashita 2 Ryuichiro Nakai 2 Chikara Murakata 2
Affiliations

Affiliations

  • 1 Fuji Research Park, Research Division, Kyowa Hakko Kirin Co., Ltd, 1188 Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731, Japan. Electronic address: junichiro.yamamoto@kyowa-kirin.co.jp.
  • 2 Fuji Research Park, Research Division, Kyowa Hakko Kirin Co., Ltd, 1188 Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731, Japan.
Abstract

The 2,4,5-substituted-1,3,4-thiadiazoline derivative 1a has been identified as a new class of mitotic Kinesin Eg5 inhibitor. With the aim of enhancement of the mitotic phase accumulation activity, structure optimization of side chains at the 2-, 4-, and 5-positions of the 1,3,4-thiadiazoline ring of 1a was performed. The introduction of sulfonylamino group at the side chain at the 5-position and bulky acyl group at the 2- and 4-position contributed to a significant increase in the mitotic phase accumulation activity and Eg5 inhibitory activity. As a result, a series of optically active compounds exhibited an increased antitumor activity in a human ovarian Cancer xenograft mouse model that was induced by oral administration.

Keywords

Mitotic kinesin Eg5 inhibitor; Thiadiazoline derivatives.

Figures